NASDAQ$CGEM
Cullinan Oncology Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Cullinan Oncology reported financial results for the first quarter ended March 31, 2021.
Cullinan Oncology reported a net income of $1.4 million for Q1 2021, which included $18.9 million in revenue from a license agreement with Zai Lab. The company's cash, cash equivalents, and investments totaled $473.0 million as of March 31, 2021.
- Initiated Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations.
- Cash, cash equivalents and investments of $473.0 million as of March 31, 2021, post completion of Initial Public Offering in early January 2021.
- Updated Cullinan Pearl data to be presented at ASCO in June 2021.
- Continued to advance CLN-619 through IND-enabling activities.
Headline financials
Revenue & EPS history
Cullinan Oncology · Revenue · Quarterly
$18.9M
Forward guidance
Cullinan Oncology anticipates continued development and expansion of its pipeline, with clinical and preclinical updates expected throughout the year. The company expects to submit INDs for CLN-619 in the second quarter of 2021 and for CLN-617 and CLN-978 in 2022, and plans for a CLN-049 IND resubmission in mid-2021.
Tailwinds
- Continued development and expansion of diverse pipeline.
- Clinical and preclinical updates expected throughout the year.
- Poster presentation with updated clinical data for Cullinan Pearl at ASCO in June.
- Updated preclinical data on Cullinan Amber at the Next-Gen Cytokine Therapeutics Summit in the third quarter.
- Advancing CLN-619 through IND-enabling activities.
Headwinds
- Uncertainty regarding the timing and results of regulatory submissions.
- Risks related to success of clinical trials and preclinical studies.
- Risks related to ability to protect and maintain intellectual property position.
- Risks related to manufacturing, supply, and distribution of therapeutic candidates.
- Potential negative impacts from COVID-19 on operations and global economies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-2.1%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+13.5%
Q1 2022
Best reaction
-10.8%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | +7.7% | -10.0% | |
| Q3 2025 | +0.8% | +6.7% | +44.9% | |
| Q2 2025 | -10.8% | -7.7% | -11.3% | |
| Q1 2025 | +2.3% | +1.3% | +5.8% | |
| Q4 2024 | +1.9% | -3.8% | -5.1% | |
| Q3 2024 | -2.8% | -2.8% | -20.8% | |
| Q1 2024 | -9.7% | -9.1% | -28.4% | |
| Q4 2023 | -6.2% | -8.7% | -1.8% | |
| Q3 2023 | -2.7% | -11.1% | -17.7% | |
| Q2 2023 | +4.3% | -1.4% | -0.6% | |
| Q1 2023 | +1.2% | -5.3% | +36.0% | |
| Q4 2022 | -1.5% | +3.3% | -9.1% | |
| Q3 2022 | +3.8% | +1.0% | -3.0% | |
| Q2 2022 | -5.6% | +0.8% | -3.5% | |
| Q1 2022 | +13.5% | +6.8% | +12.1% | |
| Q4 2021 | +8.8% | +3.0% | -8.6% | |
| Q3 2021 | -4.5% | -10.1% | -28.8% | |
| Q2 2021 | +7.8% | +3.8% | +8.0% | |
| Q1 2021 | +2.2% | +12.4% | +13.1% | |
| Q4 2020 | +9.5% | +8.4% | -13.9% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro